Preventative and therapeutic strategies for cancer stem cells

Cancer Stem Cells

Volumn , Issue , 2009, Pages 68-92

  Sell, Stewart ^a   Glinsky, Gennadi ^b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872370547     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511605536.006     Document Type: Chapter

References (144)

1. Pierce GB, Wallace C. Differentiation of malignant to benign cells. Cancer Res 1971;31:127-134. AN AACR SCIENTIFIC LANDMARK
2. Sell S, Pierce GB. Biology of disease: maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994;70:6-21. AN AACR SCIENTIFIC LANDMARK
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
4. Sell S. Stem cell origin of cancer and differentiation therapy. CR Oncol/Hematol 2004;51:1-28.
5. Sell S. Potential gene therapy for cancer stem cells. Curr Gene Ther 2006;6:579-591.
6. Sell S. Leukemia: stem cells, maturation arrest and differentiation therapy. Stem Cell Rev 2005;1:197-205.
7. O'Hare MJ. Teratomas, neoplasia and differentiation: a biological overview I. The natural history of teratomas. Invest Cell Pathol 1978;1:39-63.
8. Pierce GB, Shikes R, Fink LM. Cancer: a problem of developmental biology. Englewood Cliffs, NJ;Prentice Hall, 1978.
9. Peyron A. Sur la presence des cellules genitales primordiales dans les boutons embryonnaires des embryomes parthenogenetiques chez l’homme. CR Acad Sci (Paris) 1938;206:1680-1683.
10. Pierce GB, Dixon FJ. Testicular teratomas. I. Demonstration of teratogenesis by metamorphosis of multipotential cells. Cancer 1959;12:573-583.
11. Pierce GB, Dixon FJ, Varney IL. Teratocarcinogenic and tissue forming potentials of the cell types comprising neoplastic embryoid bodies. Lab Invest 1960;9:583-602.
12. Kleinsmith LJ, Pierce GB. Multipotentiality of single embryonal carcinoma cells. Cancer Res 1964;24:1544-1551.
13. Pierce GB, Varney EL. An in vitro and in vivo study of differentiation in teratocarci-nomas. Cancer 1961;14:1017-1029.
14. O’Hare MJ. Teratomas, neoplasia and differentiation: a biological overview. I. The natural history of teratomas. Invest Cell Pathol 1978;1:39-63.
15. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol 2003;3:338-343.
16. Strickland S, Madavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 1978;15:393-403.
17. Grover A, Adamson ED. Evidence for the existence of an early common biochemical pathway in the differentiation of F9 cells into visceral or parietal endoderm: modulation by cyclic AMP. Dev Biol 1986;114:492-503.
18. Wasylyk B, Imler JL, Chatton B, Schatz C, Wasylyk C. Negative and positive factors determine the activity of the polyoma virus enhancer alpha domain in undifferentiated and differentiated cell types. Proc Natl Acad Sci USA 1988;85:7952-7956.
19. Oshima RG, Abrams L, Kulesh D. Activation of an intron enhancer within the keratin 18 gene by expression of c-fos and c-jun in undifferentiated F9 embryonal carcinoma cells. Genes Dev 1990;4:835-848.
20. Boylan JF, Lufkin T, Achkar CC, Taneja R, Chambon P, Gudas LJ. Targeted disruption of retinoic acid receptor α (RARα) and RARγ results in receptor-mediated alterations in retinoic acid-mediated differentiation and retinoic acid metabolism. Mol Cell Biol 1995;15:843-851.
21. Choi SK, Yeh J-C, Cho M, Cummings RD. Transcriptions regulation of 1,3- galactosyltransferase in embryonal carcinoma cells by retinoic acid. J Biol Chem 1996;271:3238-3246.
22. Congyi C, Gudas LJ. Murine laminin B1 gene regulation during the retinoic acid- and dibutyryl cycic AMP-induced differentiation of embryonic stem cells. J Biol Chem 1996;271:6810-6818.
23. Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, Heyman RA, Chandraratna RAS, Shudo K, Hong WK, Lotan R. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 2000;6:1563-1573.
24. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41:41-55.
25. Mehta K. Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents 2003;17:1-12.
26. Trump DL. Retinoids in bladder, testes and prostate cancer: epidemiologic, preclinical and clinical observations. Leukemia 1994;8(Suppl 3):50-54.
27. Yoskitake T, Itoyama S. Treatment of primary mediastinal germ cell tumors. Tinsho Kyobu Geka 1989;9:29-34.
28. Bartlett NL, Freiha FS, Torti FM. Serum markers in germ cell neoplasms. Hem/Oncol Clin N Am 1991;5:1245-1260.
29. Stenman U-H, Alfthan H. Markers for testicular cancer. In Tumor markers (Diamandis E, Fritsche H, Lilha H, Chan D, Schwartz M, eds). Washington, DC; AACC Press, 2002:351-359.
30. Rowley JD. Nonrandom chromosomal abnormalities in hematologic disorders of man. Proc Natl Acad Sci U S A 1975;72:152-156.
31. Nowell PC. Diagnostic and prognostic value of chromosome studies in cancer. Ann Clin Lab Sci 1974;4:234-240. AN AACR SCIENTIFIC LANDMARK
32. Baird SM. Hepatopoietic stem cells in leukemia and lymphoma. In Stem cells handbook (Sell S, ed). Totowa, NJ;Humana Press, 2004:163-175.
33. Drucher BJ, Ralpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kan- tarjian J, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;334:1031-1037. AN AACR SCIENTIFIC LANDMARK
34. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
35. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti- Passerini C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+neoplastic cells. Cancer Res 2006;66:11314-11322.
36. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960;132:1497-1499.
37. Randolph TR. Chronic meylocytic leukemia - Part I: history, clinical presentation and molecular biology. Clin Lab Sci 2005;18:38-48.
38. Tefferi A, Dewald GE, Litsov MO, Cortes J, Mauro MJ, Talpaz M, Kantarjian HM. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc 2005;80:390-402.
39. O'Brien S, Tefferi A, Valent F. Chronic myelogenous leukemia and myeloproliferative disease. Hematology 2004:146-162.
40. Kharas MG, Fruman, DA. ABL oncogenes and phosphinositide 3-kinase: mechanism of activation and downstream effects. Cancer Res 2005;65:2047-2053.
41. Deninger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-2643.
42. Blay JY, LeCesne A, Alberti L, Ray-Coquart I. Targeted cancer therapies. Bull Cancer 2005;92:E13-E18.
43. McKenzie SB. Advances in understanding the biology and genetics of acute myelocytic leukemia. Clin Lab Sci 2005;18:28-37.
44. Goldman J. Monitoring minimal residual disease in BDR-ABL positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol 2005;12:33-39.
45. Melnick A, Licht JD. Deconstructing a disease: RARα, ins fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-3215.
46. Soignet S, Fleischauer A, Pollyak T, Heller G, Warrel RP Jr. All trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long term follow-up of the New York study. Cancer Chemother Pharmacol 1997;40:S24-S29.
47. Seeler JS, Dehean A. The PML nuclear bodies: actors or extras? Curr Opin Genet Dev 1999;9:362-367.
48. Zhong S, Salomoni P, Pandolifi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol 2000;2:E85-E90.
49. Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E. Retinoid target genes in acute promyelocytic leukemia. Leukemia 2003;17:1723-1730.
50. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;99:3167-3215.
51. Segalla S, Rinaldi L, Kilstrup-Nielsen C, Badaracco G, Minucci S, Pelicci PG, Landsberger N. Retinoic acid receptor alpha fusion to PML affects in transcriptional and chromatin-remodeling properties. Mol Cell Biol 2003;23:8795-8808.
52. Dragnev KH, Petty WJ, Dmitrovsky E. Retinoid targets in cancer therapy and chemo- prevention. Cancer Biol Ther 2003;2(Suppl 1):150-156.
53. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyan R, Andreeff M, Tafuri A, Jakubowski A, Gabilove J, Gordon MS, Smitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl Med 1991;324:1385-1393.
54. Camacho LH. Clinical application of retinoids in cancer medicine. J Biol Regul Home- ost Agents 2003;17:98-114.
55. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003;17:1454-1463.
56. Parmar S, Tallman MS. Acute promyelocytic leukaemia: a review. Expert Opin Pharmacother 2003;4:1379-1392.
57. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from North American Intergroup protocol. Blood 2002;100:4298-4302.
58. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22:7305-7315.
59. Chalandon Y, Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005;90:949-968.
60. Feldman EJ. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 2005;4:186-190.
61. Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003;102:3880-3889.
62. Levis M. Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia. Curr Opin Hematol 2005;12:55-61.
63. Robinson LJ, Xue J, Corey SJ. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 2005;33:469-479.
64. Ono R, Nakajima H, Ozaki K, Kumagai H, Kawashima T, Taki T, Kitamura T, Hayashi Y, Nosaka T. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest 2005;115:919-929.
65. Gilliand DG, Griffin JD. The role of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1332-1342.
66. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology 2004: 98-117.
67. Withers HR, Reid BO, Hussey DH. Response of mouse jejunum to multifraction radiation. Int J Radiat Oncol Biol Phys 1975;1:41-52.
68. Lange CS, Gilbert CS. Studies on the cellular basis of radiation lethality. 3. The measurement of stem-cell repopulation probability. Int J Radiat Biol Relat Stud Phys Chem Med 1968;14:373-388.
69. Peters R, Layvaz S, Perey L. Apoptotic regulation in primitive hematopoietic precursors. Blood 1998;92:2041-2051.
70. Domen J, Gandy KL, Weissman IL. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood 1998;91:2272-2282.
71. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multi-drug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
72. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-1806.
73. Hirschmann-Jax C, Foster AE, WulfGG, Nuchtern JG, Jax TW, GobelU, GoodelMA, Brenner MK. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004;101:14228-14233.
74. McCulloch EA. Normal and leukemic hematopoietic stem cells and lineages. In Stem cells handbook (Sell S, ed). Totowa, NJ;Humana Press, 2004:119-131.
75. Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996;87:4754-4761.
76. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 1997;3:730-737.
77. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007;317:337.
78. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006;66:1883-1890.
79. Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest 2006;86:1203-1207.
80. Trott KR. Tumour stem cells: the biological concept and its application in cancer treatment. Radiother Oncol 1994;30:1-5.
81. Denekamp J. Tumour stem cells: facts, interpretation and consequences. Radiother Oncol 1994;30:6-10.
82. Pierce GB, Spears WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988;48:1196-1204.
83. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res 2008;68:4018-4021.
84. Kern SE, Shibata D. The fuzzy math of solid tumor stem cells: a perspective. Cancer Res 2007;67:8985-8988.
85. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-1037.
86. Furth J, Kahn MC. The transmission of leukemia of mice with a single cell. Am J Cancer 1937;31:276-282. AN AACR SCIENTIFIC LANDMARK
87. Sell S. Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells. Stem Cell Rev 2007;3:1-6.
88. Hill RP, Perris R. Destemming cancer stem cells. J Natl Cancer Inst 2007;99:1435-1440.
89. Ivanova N, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C, Schafer X, Lun Y, Lemischka IR. Dissecting self-renewal in stem cells with RNA interference. Nature 2006;442:533-538.
90. Sell S (ed). Cancer and stem cell signaling [special issue]. Stem Cell Rev 2007;3:1-103.
91. Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 2007;3:7-17.
92. Farnie G, Clarke RB. Mammary stem cells and breast cancer - role of Notch signaling. Stem Cell Rev 2007;3:169-175.
93. Menendez P, Wang L, Bhatia M. Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications. Curr Gene Ther 2005;5:375-385.
94. Hay DC, Sutherland L, Clark J, Burdon T. Oct4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. Stem Cells 2004;22:225-235.
95. Matin MM, Walsh JR, Gokhale PJ, Draper JS, Bahrami AR, Morton I, Moore HD, Andrews PW. Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells. Stem Cells 2004;22:659-668.
96. Zaehres H, Lensch ME, Daheron J, Stewart SA, Itskovitz-Eldor J, Daley GQ. High efficiency RNA interference in human embryonic stem cells. Stem Cells 2005;23:299-305.
97. Sprading A, Drummond-Barbarosa D, Kai T. Stem cells find their niche. Nature 2002;414:98-104.
98. Wodarz A, Nusse E. Mechanisms of Wnt signaling pathways in development. Annu Rev Cell Dev Biol 1998;14:59-88.
99. Tai M-H, Chang C-C, Olson K, Trosko JE. Oct-4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005;26:495-502.
100. Nicholoff BJ, Hendrix MJ, Pollock PM, Trent JM, Miele L, Zin JZ. Notch and NOXA- related pathways in melanoma cells. J Invest Dermatol Symp Proc 2005;10:95-104.
101. Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia 2004;9:145-163.
102. Kubo M, Nakamura M, Tasaki A, Yamanaka N, Nakashima H, Homura M, Kuroki S, Katano M. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 2004;64:6071-6074.
103. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther 2004;3:36-41.
104. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004;9:119-131.
105. Milovanovic T, Planutis K, Nguyen A, Marsh JL, Lin F, Hope C, Holcombe RF. Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. IntJ Oncol 2004;25:1337-1342.
106. Katoh M. Expression and regulation of Wnt-1 in human cancer: up-regulation of Wnt-1 by beta-estradiol in MCF-7 cells. IntJ Oncol 2003;22:209-212.
107. Saitoh T, Katoh M. Expression and regulation of WNT5A and WNT5B in human cancer: up-regulation of WNT5A by TNFalpha in MKN45 cells and up-regulation of WNT5B by beta-estradiol in MCF-7 cells. IntJ Mol Med 2002;10:345-349.
108. Katoh M. Regulation of WNT3 and WNT3A mRNAs in human cancer cell lines. IntJ Oncol 2002;20:373-377.
109. Mishra L, Shetty K, Tang Y, Stuart A, Byers SW. The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005;24:5775-5789.
110. Nagae Y, Kameyama K, Yokoyama M, Naito Z, Yamada N, Maeda S, Asano G, Sugisaki Y, Tanaka S. Expression of E-cadherin, catenin and C-erb-2 gene products in invasive ductal-type breast carcinomas. J Nippon Med Sch 2002;69:165-171.
111. Jaing WG, Mansel RE. E-cadherin complex and its abnormal sites in human breast cancer. Surg Oncol 2000;9:151-171.
112. Lu Z, Ghosh S, Wang Z, Hunter T. Down-regulation of caveolin-1 function by EGF leads to loss of E-cadherin, increased transcriptional activity of p-catenin, and enhanced tumor cell invasion. Cancer Cell 2003;4:499-515.
113. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pckaj B, Gendler SJ. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 2002;277:22692-22698.
114. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death from cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-1521.
115. Glinsky GV. Death-from-cancer signatures and contribution of stem cells to metastatic cancer. Cell Cycle 2005;4:1171-1175.
116. Glinsky GV. Genomic models of metastatic cancer: functional analysis of death-from- cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 2006;5:1208-1216.
117. Glinsky GV. Integration of HapMap-based SNP pattern analysis and gene expression profiling reveals common SNP profiles for cancer therapy outcome predictor genes. Cell Cycle 2006;5:2613-2625.
118. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-6071.
119. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006;5:1886-1901.
120. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2008;111(3):419-427.
121. Rye PD, Stigbrand T. Interfering with cancer: a brief outline of advances in RNA interference in oncology. Tumor Biol 2004;25:329-336.
122. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003;327:761-776.
123. Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: Approaching effective cancer therapies. Cancer Res 2008;68:1247-1250.
124. Pirollo KF, Rait A, Zhou Q Hwang SH, Dagata JA, Zon G, Hogrefe RI, Palchik G, Chang EH. Materializing the potential of small interfering RNA via tumor-targeting nanodelivery system. Cancer Res 2007;67:2938-2943.
125. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific ologodeoxynucleotide. Proc Natl Acad Sci U S A 1978;75:280-284.
126. Harrington KJ, Nutting CM, Pandha HS. Gene therapy for head and neck cancer. Cancer Metastasis Rev 2005;24:147-164.
127. Skorski T, Neiborowska-Skorska M, Barletta C, Malaguamera L, Szczylik C, Chen S-T, Lang B, Calabretta B. Highly efficient elimination of Philadelphia1 leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 1993;92:194-202.
128. Liebermann TA, Zerbini LF. Targeting transcription factors for cancer gene therapy. Curr Gene Ther 2006;6:17-33.
129. Hanazono Y, Asano T, Ueda Y, Ozawa K. Genetic manipulation of primate embryonic and hematopoietic stem cells with simian lentivirus vectors. Trends Cardiovasc Med 2003;13:371-378.
130. Ikawa M, Tanaka N, Kao WW, VermaIM. Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. Mol Ther 2003;8:666-673.
131. Al-Haji M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MR. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988.
132. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gel- man RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-273.
133. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008;61:553-560.
134. Roskoski R Jr. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun 2005;338:1307-1315.
135. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase Kit. Stem Cells 2005;23:16-43.
136. van de Bijver M. Gene-expression profiling and the future of adjuvant therapy. Oncologist 2005;10(Suppl 2):30-34.
137. Toren A, Bielora B, Jacob-Hirsch J, Fisher T, Kreiser D, Moran O, Zeligson S, Givol D, Yitzhaky-Eldor J, Kventsel I, Rosenthal E, Amarigilio N, Rechavi R. CD133-positive hematopoietic stem cell “sternness” genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells 2005;23:1142-1153.
138. Dar A, Goichberg P, Shinder V, Kalinkovich A, Kollet O, Netzer N, Margalit R, Zsak M, Nagler A, Hardan I, Resnick I, Rot A, Lapidot T. Chemokine receptor CXCR4- dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nature Immunol 2005;6:1038-1046.
139. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000;100:157-168.
140. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OS, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005;121:1109-1121.
141. Sell S. Oncodevelopmental antigens: a review. Cancer Biol Rev 1980;1:251-352.
142. Nomura K, Nagano K, Itagaki C, Raoka M, Okamura N, Yamauchi Y, Sugano S, Takahashi N, Izumi T, Isobe T. Cell surface labeling and mass spectrometry reveal diversity of cell surface markers and signaling molecules expressed in undifferentiated mouse embryonic stem cells. Mol Cell Proteomics 2005;4:1968-1976.
143. Deicher R, Hori WH. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anemia of chronic kidney disease. Drug 2004;54:499-509.
144. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.